Axon Enterprise, Inc (NASDAQ:AXON) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Axon Enterprise, Inc (NASDAQ:AXON) have received a consensus recommendation of “Moderate Buy” from the nineteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $712.75.

A number of research firms have recently issued reports on AXON. Needham & Company LLC cut their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Royal Bank Of Canada cut their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. UBS Group cut their target price on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Morgan Stanley set a $600.00 target price on shares of Axon Enterprise in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group set a $535.00 target price on shares of Axon Enterprise in a research note on Thursday, May 7th.

Insiders Place Their Bets

In other Axon Enterprise news, President Joshua Isner sold 13,000 shares of Axon Enterprise stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $488.45, for a total value of $6,349,850.00. Following the completion of the sale, the president owned 169,125 shares in the company, valued at $82,609,106.25. The trade was a 7.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of Axon Enterprise stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $485.00, for a total transaction of $753,690.00. Following the completion of the sale, the insider owned 34,024 shares of the company’s stock, valued at $16,501,640. This trade represents a 4.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 38,989 shares of company stock worth $19,090,083. 4.20% of the stock is currently owned by insiders.

Institutional Trading of Axon Enterprise

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Evergreen Capital Management LLC raised its stake in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares in the last quarter. Wealth Alliance LLC raised its stake in Axon Enterprise by 3.2% in the 3rd quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company’s stock worth $419,000 after purchasing an additional 18 shares in the last quarter. Quadrant Capital Group LLC raised its stake in Axon Enterprise by 0.5% in the 3rd quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company’s stock worth $2,848,000 after purchasing an additional 19 shares in the last quarter. CWA Asset Management Group LLC raised its stake in Axon Enterprise by 5.2% in the 4th quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 19 shares in the last quarter. Finally, Synergy Financial Group LTD raised its stake in Axon Enterprise by 1.4% in the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock worth $996,000 after purchasing an additional 19 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $443.21 on Tuesday. The firm has a 50-day moving average of $410.95 and a 200-day moving average of $488.34. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The stock has a market cap of $35.72 billion, a PE ratio of 178.00, a P/E/G ratio of 8.03 and a beta of 1.45. Axon Enterprise has a 52-week low of $339.01 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The company had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. Axon Enterprise’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.47 EPS. On average, sell-side analysts anticipate that Axon Enterprise will post 1.82 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.